Agent-based modeling of cellular dynamics in adoptive cell therapy.

Area of Science:

• Immunology
• Computational Biology
• Cancer Research

Background:

• Adoptive cell therapies (ACT) show promise for cancer treatment by harnessing tumor-immune interactions.
• Understanding the molecular mechanisms and cellular properties driving clinical success in chimeric-antigen-receptor natural killer (CAR-NK) cell therapies remains crucial.
• Current experimental models (in vitro, in vivo) are costly, labor-intensive, and limited in scope.

Purpose of the Study:

• To develop an in silico approach for simulating tumor-immune ecosystem dynamics in adoptive cell therapy.
• To identify critical cellular properties and therapeutic strategies for enhancing ACT efficacy across diverse cancers.
• To provide a platform for systematic in silico trials to guide ACT product development.

Main Methods:

• Development of ABMACT (Agent-Based Model for Adoptive Cell Therapy), an agent-based modeling (ABM) framework.
• Simulation of heterogeneous tumor-immune ecosystems using virtual cells based on experimental and patient omics data.
• Application of the model in various therapeutic contexts to analyze ACT dynamics.

Main Results:

• The study identified key factors for optimal ACT efficacy: enhanced immune cellular proliferation, cytotoxicity, and serial killing capacity.
• ABMACT successfully simulated the continuous course and dynamics of evolving tumor-immune interactions.
• In silico trials demonstrated the model's utility in predicting treatment outcomes.

Conclusions:

• ABMACT offers a powerful computational tool to explore complex tumor-immune dynamics in ACT.
• The model can systematically inform ACT product development and predict optimal treatment strategies.
• Enhancing specific immune cell functions is critical for maximizing the clinical benefits of adoptive cell therapies.